50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
NASDAQ:XENT

Intersect ENT - XENT Stock Forecast, Price & News

$28.24
0.00 (0.00%)
(As of 09/16/2022)
Add
Compare
Today's Range
$28.24
$28.24
50-Day Range
$28.24
$28.24
52-Week Range
$15.92
$28.25
Volume
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XENT stock logo

About Intersect ENT (NASDAQ:XENT) Stock

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Stock News Headlines

DexCom (DXCM) Misses Q1 Earnings Estimates
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
See More Headlines
Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Company Calendar

Last Earnings
11/02/2021
Today
9/24/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENT
Employees
433
Year Founded
N/A

Profitability

Net Income
$-159,630,000.00
Net Margins
-161.94%
Pretax Margin
-163.16%

Debt

Sales & Book Value

Annual Sales
$106.75 million
Book Value
($2.06) per share

Miscellaneous

Free Float
33,104,000
Market Cap
$954.91 million
Optionable
Optionable
Beta
1.45

Key Executives

  • Mr. Thomas A. West (Age 58)
    Pres, CEO & Director
    Comp: $908.97k
  • Mr. Richard A. Meier (Age 62)
    Exec. VP & CFO
    Comp: $621.76k
  • Mr. Patrick A. Broderick (Age 63)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $138.46k
  • Ms. Reyna M. Fernandez
    Chief Human Resource Officer
  • Mr. Drake R. Parker (Age 58)
    Advisor of Strategic Initiatives













XENT Stock - Frequently Asked Questions

How have XENT shares performed in 2022?

Intersect ENT's stock was trading at $27.31 at the beginning of the year. Since then, XENT stock has increased by 3.4% and is now trading at $28.24.
View the best growth stocks for 2022 here
.

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?
What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different retail and institutional investors. Top institutional shareholders include CSS LLC IL (0.00%). Insiders that own company stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends
.

How do I buy shares of Intersect ENT?

Shares of XENT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $28.24.

How much money does Intersect ENT make?

Intersect ENT (NASDAQ:XENT) has a market capitalization of $954.91 million and generates $106.75 million in revenue each year. The medical equipment provider earns $-159,630,000.00 in net income (profit) each year or ($4.79) on an earnings per share basis.

How many employees does Intersect ENT have?

The company employs 433 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The official website for the company is www.intersectent.com. The medical equipment provider can be reached via phone at (650) 641-2100, via email at ir@intersectent.com, or via fax at 866-736-1251.

This page (NASDAQ:XENT) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.